Inocucor closes Series B round at $50.9 mln, opens Denver HQ
Inocucor Corp, a developer of biological inputs for high-value produce and row crops, has raised an additional $12.1 million (US$9.5 million) for its Series B financing. The tranche was led by U.S. food and agriculture investor Pontifax AgTech and joined by Cycle Capital Management, Desjardins Innovatech and Cairn Investments. It brings the total value of the round, initially closed last year, to $50.9 million (US$38.5 million). Founded in 2007 in Montréal, Inocucor has with the Series B opened a new headquarters in Denver, Colorado. It will use the funds raised for the opening, a new production facility, commercialization of two biostimulants, and development of biocontrol products.
8 January 2018•4 mins read
